Presentation is loading. Please wait.

Presentation is loading. Please wait.

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Published byKarl Pettersson Modified over 5 years ago

Similar presentations

Presentation on theme: "Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),"— Presentation transcript:

1 Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis), noninflammatory controls, and disease controls (unrelated CTD). Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis), noninflammatory controls, and disease controls (unrelated CTD). MATTHEW L. STOLL et al. J Rheumatol 2011;38: ©2011 by The Journal of Rheumatology

Download ppt "Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),"

Similar presentations

Total Knee Arthroplasty in Juvenile Rheumatoid Arthritis by David H. Palmer, Kevin J. Mulhall, Corey A. Thompson, Erik P. Severson, Edward R.G. Santos,

Total Knee Arthroplasty in Juvenile Rheumatoid Arthritis by David H. Palmer, Kevin J. Mulhall, Corey A. Thompson, Erik P. Severson, Edward R.G. Santos,

 The Juvenile Arthritis Foot Disability Index (JAFI) (Andre et al, 2004) was the primary outcome measure of the impact of JIA on the foot.  The Child.

 The Juvenile Arthritis Foot Disability Index (JAFI) (Andre et al, 2004) was the primary outcome measure of the impact of JIA on the foot.  The Child.
Lyme Arthritis in Children Presenting with Joint Effusions by Matthew D. Milewski, Aristides I. Cruz, Christopher P. Miller, Ashley T. Peterson, and Brian.

Lyme Arthritis in Children Presenting with Joint Effusions by Matthew D. Milewski, Aristides I. Cruz, Christopher P. Miller, Ashley T. Peterson, and Brian.
?. Transition of care in patients with Juvenile Idiopathic Arthritis Philomine van Pelt, rheumatologist, trainee in paediatric rheumatology Wilhelmina.

?. Transition of care in patients with Juvenile Idiopathic Arthritis Philomine van Pelt, rheumatologist, trainee in paediatric rheumatology Wilhelmina.
Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
به نام خدا.

به نام خدا.
Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).
Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
by Gillian C Hall, Louise E Tulloh, and Robert M R Tulloh

by Gillian C Hall, Louise E Tulloh, and Robert M R Tulloh
Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 4 Antinuclear antibodies and disease activity in SLE
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.
Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 2 Shared genetic loci in systemic autoimmune diseases
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Patient disposition during open-label longterm exposure period.

Patient disposition during open-label longterm exposure period.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Similar presentations

Ads by Google